Journal
CLINICAL INFECTIOUS DISEASES
Volume 73, Issue 7, Pages E1762-E1765Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciaa1474
Keywords
SARS-CoV-2; remdesivir; RNA-dependent RNA-polymerase mutation; COVID-19; convalescent plasma
Categories
Ask authors/readers for more resources
A 76-year-old female with post-rituximab B-cell immuno-deficiency and persistent SARS-CoV-2 viremia developed a mutation in RdRP (D484Y) following treatment with remdesivir, but was successfully cured after supplementation with convalescent plasma.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly discovered virus for which remdesivir is the only antiviral available. We report the occurrence of a mutation in RdRP (D484Y) following treatment with remdesivir in a 76-year-old female with post-rituximab B-cell immuno-deficiency and persistent SARS-CoV-2 viremia. A cure was achieved after supplementation with convalescent plasma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available